News
What Managed Care Organizations Are, and How Investors Can Profit From Them
Most Americans get their healthcare through a managed care organization, but nearly no one truly knows the ins and outs of the health insurance program they have. Managed care organizations are plans
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months
Although there is some truth in the saying that it takes money to make money, that doesn't mean investors can't start small and reap big rewards. With little more than $1,000 in your account, you can
Is Aurinia Pharmaceuticals' Management Its Best Asset?
Richard Glickman was the founder and CEO of Aspreva Pharmaceuticals, a small company that he sold for $915 million in 2008 after it developed CellCept, a treatment that today is commonly used in lupus
Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?
Despite a widespread rally across the biotech landscape last month, the struggling clinical-stage cancer company Celldex Therapeutics (NASDAQ: CLDX) still managed to shed 14.8% of its value in
5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there's the third type of marijuana stock: the
Is It Time to Sell Portola?
Portola Pharmaceuticals' (NASDAQ: PTLA) stock recently jumped 45% on the news that it won its first FDA approval.In this segment of Industry Focus: Healthcare, Motley Fool analyst Kristine Harjes and
No Surprise! Amicus Therapeutics Hits Up Investors for More Cash
Amicus Therapeutics (NASDAQ: FOLD) will be able to submit its Fabry disease drug Galafold to the FDA for consideration, a reversal of fortune that sent shares skyrocketing earlier this week. While
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug
1 Reason Why Cara Therapeutics Ended June Down 11.3%
Cara Therapeutics (NASDAQ: CARA), a clinical-stage biotech developing treatments for pain and chronic kidney disease-associated pruritus (itching), gave investors an absolutely wild ride last month
Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back
Investors in Alder Biopharmaceuticals (NASDAQ: ALDR) are having another wild day. Shares of the clinical-stage biopharma rose as much as 15.5% on Thursday after the company released the pricing
Johnson & Johnson Looks for Second-Quarter Strength to Keep Upward Momentum
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) has been immensely successful over the years, and it has also done well for shareholders recently. With a nearly 15% rise so far in 2017, Johnson
Johnson & Johnson Looks for Second-Quarter Strength to Keep Upward Momentum
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) has been immensely successful over the years, and it has also done well for shareholders recently. With a nearly 15% rise so far in 2017, Johnson
Portola's Hitting All-Time Highs: Here's Why the Stock Should Go Higher
Portola Pharmaceuticals' (NASDAQ: PTLA) won FDA approval of their first commercial drug, Bevyxxa in June, and that sent shares skyrocketing. Yet the market opportunity for Bevyxxa could total in the
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 30 juin 2017
Le 10 juillet 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Freitagsfrage – Was versteht man unter PEPP?
Die EU liebt bekanntlich Abkürzungen! Nun will sie die private Altervorsorge der Europäer auf-„pepp“-en. Ende Juni hat die EU-Kommission daher Vorschläge für eine Europa-Rente auf den Tisch gelegt
Freitagsfrage – Was versteht man unter PEPP?
Die EU liebt bekanntlich Abkürzungen! Nun will sie die private Altervorsorge der Europäer auf-„pepp“-en. Ende Juni hat die EU-Kommission daher Vorschläge für eine Europa-Rente auf den Tisch gelegt
BASTIDE : Mise en place de nouveaux financements bancaires - De fortes ambitions en croissance externe
Le Groupe Bastide annonce la signature d'un accord avec le pool bancaire pour la mise en place d'un nouveau crédit syndiqué pour un montant de 155 M€, qui englobe le refinancement du crédit....
BOIRON : Bilan semestriel du contrat de liquidité - S1 2017
Le 5 juillet 2017
Bilan semestriel du contrat de liquidité BOIRON
contracté avec NATIXIS
Au titre du contrat de liquidité confié à NATIXIS portant sur les actions de la société BOIRON, à la....
BASTIDE : Bilan semestiel du contrat de liquidité au 30 juin 2017
Société anonyme au capital de 3.303.261 €
Siège social : Centre d'activité Euro 2000, 12, avenue de la Dame, BP 28, 30132 Caissargues.
305 635 039 R.C.S. Nîmes.
Exercice social : du....
BASTIDE : Nombre d'actions et de droits de vote au 30 juin 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....